ArticleAIDS (London, England)2015
Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM.
Article in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review.BMC public health · 2021Pooled it
- Systematic review of mobile health behavioural interventions to improve uptake of HIV testing for vulnerable and key populations.Journal of telemedicine and telecare · 2017Pooled it
- Exploring the feedback effects of incentive methods on HIV rapid self-testing among men who have sex with men in Chongqing, China.BMC public health · 2025Trial
- Trial
- Effects of a Mobile Health Intervention to Promote HIV Self-testing with MSM in China: A Randomized Controlled Trial.AIDS and behavior · 2019Trial
- Modelling HIV/AIDS epidemiological complexity: A scoping review of Agent-Based Models and their application.PloS one · 2024Article
- The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis.The lancet. HIV · 2023Article
- Impact of voluntary testing on infectious disease epidemiology: A game theoretic approach.PloS one · 2023Article
- Motivations and Barriers to Routine HIV Testing Among Men Who Have Sex with Men in New York City.AIDS and behavior · 2022Article
- Predictors of HIV Among 1 Million Clients in High-Risk Male Populations in Tanzania.AIDS and behavior · 2022Article
- Observational
- Development and Evaluation of a Mobile App Designed to Increase HIV Testing and Pre-exposure Prophylaxis Use Among Young Men Who Have Sex With Men in the United States: Open Pilot Trial.Journal of medical Internet research · 2021Article
- Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Exploring Mechanisms of Action: Using a Testing Typology to Understand Intervention Performance in an HIV Self-Testing RCT in England and Wales.International journal of environmental research and public health · 2020Article
- Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities.Journal of the International AIDS Society · 2019Article
- Article
- Preferences for HIV testing services among men who have sex with men in the UK: A discrete choice experiment.PLoS medicine · 2019Article
- A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.BMC infectious diseases · 2018Article
- HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIncreased rates of testing, with early antiretroviral therapy (ART) initiation, represent a key potential HIV-prevention approach. Currently, in MSM in the United Kingdom, it is estimated that 36% are diagnosed by 1 year from infection, and the ART initiation threshold is at CD4 cell count 350/μl. We investigated what would be required to reduce HIV incidence in MSM to below 1 per 1000 person-years (i.e. <535 new infections per year) by 2030, and whether this is likely to be cost-effective.
methodsA dynamic, individual-based simulation model was calibrated to multiple data sources on HIV in MSM in the United Kingdom. Outcomes were projected according to future alternative HIV testing and ART initiation scenarios to 2030, considering also potential changes in levels of condomless sex.
resultsFor ART use to result in an incidence of close to 1/1000 person-years requires the proportion of all HIV-positive MSM with viral suppression to increase from below 60% currently to 90%, assuming no rise in levels of condomless sex. Substantial increases in HIV testing, such that over 90% of men are diagnosed within a year of infection, would increase the proportion of HIV-positive men with viral suppression to 80%, and it would be 90%, if ART is initiated at diagnosis. The scenarios required for such a policy to be cost-effective are presented.
conclusionThis analysis provides targets for the proportion of all HIV-positive MSM with viral suppression required to achieve substantial reductions in HIV incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.